Biomarker Partnering Terms and Agreements, Worldwide, 2014 to 2020 - Provides Access to Headline, Upfront, Milestone and Royalty Data

News provided by

May 14, 2020, 18:30 ET

DUBLIN, May 14, 2020 /PRNewswire/ -- The "Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the world's leading healthcare companies.

In-depth understanding of biomarker deal trends since 2014
Access to headline, upfront, milestone and royalty data
Analysis of the structure of biomarker agreements with numerous real life case studies
Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies
Access to most active biomarker dealmakers since 2014
Insight into the terms included in a biomarker agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The report provides a detailed understanding and analysis of how and why companies enter Biomarker partnering deals and also includes software technologies. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Biomarker agreements announced in the healthcare sectors. The report takes readers through the comprehensive biomarker deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering biomarker partnering deals.

The report presents average financial deal terms values for biomarker deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the biomarker partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This - Chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 450 online deals records of actual biomarker deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Analyzing actual contract agreements allows assessment of the following:

What are the precise biomarker rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

4D Pharma
23andMe
A*STAR Agency for Science
Technology and Research
A*STAR Bioprocessing Technology Institute
Abbott Laboratories
Abbvie
Abcodia
Abramson Cancer Center
Academic Medical Center
Accelerate Diagnostics
Accu Reference Medical Laboratory
AC Immune
Acumen Pharmaceuticals
Adaptive Biotechnologies
Adarza BioSystems
ADC Therapeutics
Aelan Cell Technologies
Aerocrine
AFFiRiS
Affymetrix
Age Labs
Agendia
Air Force Research Laboratory
AIT Laboratories
Akers Biosciences
Akili Interactive Labs
Albert Einstein College of Medicine
Alector
Alion Pharmaceuticals
Almac Diagnostics
ALS Association
ALS Finding a Cure Foundation
Alzeca Biosciences
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Alzheimers Research UK
Amarantus BioSciences
Amarna Therapeutics
Ambiopharm
American Association for Cancer Research
American Association of Neuromuscular & Electrodiagnostic Medicine
American Diabetes Association
Amgen
AMRA
Anavex Life Sciences
Apogenix
Applied DNA Sciences
Arbor Biotechnologies
Arcis Biotechnology
Arcus Biosciences
AroCell
Arrow Diagnostics
Artialis
Ascenion
Association for Frontotemporal Degeneration
Astellas Pharma
Asterand Bioscience
Asthma UK
AstraZeneca
Astute Medical
Asuragen
Australian Imaging
Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
Austrian Institute of Technology
Autifony Therapeutics
Avera Heart Hospital of South Dakota
Aviana Molecular Technologies
Ayasdi
AyoxxA Biosystems
Banyan Biomarkers
Baxter International
Bayer
Bayer Healthcare
Baylor College of Medicine
Berg
Bertin Pharma
Beth Israel Deaconess Medical Center
BGI Tech Solutions
Bill and Melinda Gates Foundation
Bio-Techne
BioArctic Neuroscience
Biocartis
Biocept
Biodesix
BioDiscovery
Biogen
Biognosys
BioMarker Strategies
Biomedical Catalyst Fund (UK)
bioMerieux
BiomX
BioPorto
Biopsy Sciences
Biothera
BioTheranostics
BioVendor
Bird Foundation
Blackfynn
BlackThorn Therapeutics
Blinktbi
BluePen Biomarkers
Blueprint Medicines
Boehringer Ingelheim
Bonnie J. Addario Lung Cancer Foundation
Brain Biomarker Solutions in Gothenburg
BrainScope
Breath Diagnostics
Brigham and Women's Hospital
Bristol-Myers Squibb
Broad Institute
Buck Institute for Age Research
C2N Diagnostics
Cachet Pharma
California Stem Cell
Cambridge Epigenetix
Cambridge Isotope Laboratories
CANbridge Life Sciences
Cancer Genetics
Cancer Immunotherapy Trials Network
Cancer Research Institute
Cancer Research UK
Caprion Biosciences
Caprion Proteomics
Caris Life Sciences
Carmentix
Carolinas Medical Center (CMC)
Case Western Reserve University
CASI Pharmaceuticals
Catalyn Medical Technologies
Catholic University Leuven
CBD Solutions
Cedars-Sinai Medical Center
Celgene
Cellgen Diagnostics
Celmatix
Celsee
Celsius Therapeutics
Cenix BioScience
Center for Biomarker Research in Medicine
Center for Human Immunology
Autoimmunity and Inflammation
Centers for Disease Control and Prevention
Centre for Drug Research and Development (CDRD)
Centre for Imaging Technology Commercialization
Centre Hospital University - Bordeaux
Centre Leon Berard
Centre National de la Recherche Scientifique
Certis
Cerveau Technologies
CHDI Foundation
Chembio Diagnostics
Children's Hospital Boston
Children's Medical Research Institute
Children's Research Institute
Children's Hospital Colorado
Christian Doppler Research Association
Cincinnati Children's Hospital Medical Center
Circulogene
Cleveland Clinic
Cleveland HeartLab
Clinical Genomics
Cloud Pharmaceuticals
Cognition Therapeutics
Cohen Veterans Bioscience
Columbia University
COPD Foundation
Cornell University
Covance
CRC Health
Critical Diagnostics
Crohn's and Colitis Foundation of America
Crossbeta Biosciences
CSIRO
Curetis
Curie-Cancer
Cypher Genomics
Cytox
Daiichi Sankyo
Dako
Dana-Farber Cancer Institute
Danish Center for Strategic Research into Type 2 Diabetes
Defense Advanced Research Projects Agency
Definiens
Department of Defense
Department of Veterans Affairs

For more information about this report visit https://www.researchandmarkets.com/r/ygoqvh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets